Can a Child's own words improve cancer care?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 2 to 18 years * Patients aged 8 to 18 years who can read French, English, or Spanish fluently OR patients aged 6 to 7 years who can read French, English, or Spanish fluently, OR patients aged 2 to 7 years who cannot read fluently but whose parents can read French, English, or Spanish fluently * Patients included in the SACHA study before starting treatment * Patients with a pediatric tumor or leukemia who have failed treatment or relapsed and have no standard treatment options available OR patients receiving first-line treatment with no standard treatment options available (e.g., inoperable plexiform neurofibroma and MEK inhibitors, infantile fibrosarcoma and NTRK inhibitors) * Not eligible for an open early-phase clinical trial in France, or declining participation * Treated with a new innovative medicinal product and discussed at a RCCPI meeting under a granted early access authorization or compassionate use authorization issued by the ANSM, or receiving off-label use of a medicinal product already authorized in adults * Treated in one of the SFCE centers authorized to prescribe chemotherapy * The holders of parental authority have stated their non-opposition to their child's participation in the study after being informed. Minors will receive age-appropriate information adapted to their level of understanding. If the minor is emancipated, they will provide non-opposition directly * A patient who is prescribed another innovative therapy and is re-included in SACHA may be included again in PRO-SACHA Exclusion Criteria: * Patient who has already started the innovative treatment * Patients aged 8 years and older who cannot read * Patients whose clinical condition does not allow them to report symptoms themselves (i.e., non-communicative patient; judgment left to the investigator's discretion) * Patients currently enrolled in an early-phase trial * Refusal of participation by the patient or their legal representatives * Patient unable to express consent to participate in the study